CorriX has been highlighted as “Next-Generation Probiotic (NGP)” in a review article, “Nature”, globally renowned scientific journal, showcasing its scientific excellence.

CorriX does not contain toxic genes. The efficacy to increase the level of TFα IgM antibody in the body has been demonstrated through human study.

In the review article, CorriX is introduced as a microbiome with immune surveillance functionality against cancer cells due to its effect on increasing TFα IgM antibody levels.

This highlights that CorriX goes beyond other probiotics, playing a crucial role in enhancing immunity, maintaining health, and preventing diseases.

As such, the immunological efficacy of CorriX positions it as a scientifically valuable material with the potential to provide innovative solutions not only for immune enhancement but also in the fields of disease prevention and treatment.